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A COMPARATIVE STUDY ON THE EFFECTS OF INDOMETHACIN AND 
NABUMETONE ON RENAL FUNCTION IN CONSCIOUS AND 
ANAESTHETIZED RATS. 
INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely prescribed 
agents in the treatment of pain, fever and inflammation ( 1 ). They exert their anti-
inflammatory, analgesic and antipyretic effects through the inhibition of 
prostaglandin synthesis by blocking cyclooxygenase (COX) activity, a major 
enzyme in the biosynthesis of all prostaglandins (2). 
Prostaglandins are ubiquitous in their distribution throughout the body and 
function for most part as "local hormones". Kidney is extremely acti·Je in the 
biosynthesis and mechanism of prostaglandins. These compounds participate in 
several processes in renal physiology, including autoregulation of renal blood 
flow and glomerular filtration rate, modulation of renin release, tubular ion 
transport and water metabolism(3). 
COX is a key enzyme regulating the formation of prostaglandins from arachidonic 
acid. Recently however, COX was discovered to have two isoform namely COX-
1 and COX-2 ( 4 ). These are derived from different genes but share -60°/o amino 
acid identity. The expression patterns of COX-1 and COX-2 genes are quite 
different (5). COX-1 is normally expressed in the gastrointestinal tract, kidney 
and platelets and thought to participate in housekeeping function. It appears to 
be responsible for mediating the production of thromboxane and prostaglandins. 
Under the influence of COX-1, prostaglandins maintain the integrity of the gastric 
mucosa, mediate normal platelet function and regulate renal blood flow during 
states of hemodynamic stress (6). 
The isoenzyme COX-2 is primarily associated with inflammation (7). Cytokines 
and growth factors increase the expression of COX-2 at inflammatory sites, 
producing prostaglandins that mediate inflammation, pain and fever. The 
discovery of the COX-2 isoenzyme has led to believe that COX-2 selective 
inhibition would provide the potent anti-inflammatory, analgesic and antipyretic 
effects that have been associated with the traditional NSAIDs with less side 
effects especially on renal function(8). 
Traditional NSAIDs such as ibuprofen, indomethacin, aspirin and naproxen which 
inhibit both COX-1 and COX-2 are known to produce deleterious effects on renal 
function. particularly durirg haemodynamically stressful situations (9). This 
includes patients and individuals with decreased effective blood volume causesd 
by cardiac failure ( 1 0), liver cirrhosis with ascites ( 11 ), renal insufficiency ( 12) 
and hypertension (13). Responses to these hemodynamic challenges include 
stimulation of the renin-angiotensin-aldosterone axis, with enhanced production 
of renin, the vasoconstrictive angiotensin II and aldosterone, which promotes 
sodium, water and chloride reabsorption and elevated sympathetic outflow, which 
further tend to promote vascular tone (14). In these situations, prostaglandins 
promote compensatory vasodilation of renal vascular beds to ensure an 
adequate blood supply and preclude acute functional deterioration of the kidney 
(15). But NSAIDs blunted these prostaglandins production and may cause 
further marked decreases in renal blood flow, glomerular filtrcltion rate (GFR) and 
renal excretion of sodium and water, hyperkalemia and hyponatriemia (16). 
However, little information exists regarding the effects of COX-2 inhibition on 
renal function. 
Most studies investigating the effects of the traditional NSAIDs on renal function 
have used animal models that have been anaesthetized. A recent study on rats 
in our laboratory using an NSAID, naproxen, has shown renal effects of naproxen 
that are opposite to what has been observed previously in anaesthetized rats 
( 17), suggesting perhaps that the effects of NSAIDs on renal function may 
depend on the experimental design. This study therefore proposes to 
reinvestigate the effects of indomethacin on renal function in conscious and 
anaesthetized rats. In addition, we also propose to similarly study the effects of a 
COX-2 selective inhibitor, nabumetone, on renal function in the same species. 
OBJECTIVE 
The main objectives of the study are to : 
1. Investigate the effects of indomethacin on renal function in both 
·anaesthetized and conscious rats. 
2. Investigate the effects of nabumetone on renal function in both 
anaesthetized and conscious rats. 
3. Compare the effects of indomethacin and nabumetone on renal 
function in both anaesthetized and conscious rats. 
• 
MATERIAL AND METHODS 
Study design. For conscious rats, thirty male Sprague Dawley rats weighing 
between 200-220 gram were housed· individually in metabolic cages for a total 
duration of 5 weeks. The protocol consisted of four phases, namely; 
acclimatization phase (1 week), control phase (1 week), experimental phase (2 
weeks) and recovery phase (1 week). All animals were treated identically during 
the acclimatization, control and the recovery phases. During the experimental 
phase however, the animals were given orally either 1.5mg.kg·1 body weight/day 
twice of indomethacin (n = 1 0), or 15mg.kg"1 body weight/day once of 
nabumetone (n = 1 0), dissolved in 0.5 ml of saline for a period of two weeks. 
Animals for control group (n = 1 0) were given only 0.5ml of saline. Food and 
water were provided ad-libitum and water intake, food intake, body weight, urine 
output, urinary sodium, potassium, calcium, magnesium, osmolality, osmolar and 
microalbumin excretion were estimated in all animals. 
Study design. For anaesthetized rats, thirty two overnight fasted, male Sprague 
- Dawley rats but with access to water ad libitum and weighing between 230-
260gm were prepared for standard clearance experiments. Followin~ 
anaesthetization with an intraperitoneal injection of sodium thiopental (60mg.kg· 
body weight), the jugular vein and carotid artery were cannulated for continuous 
normal saline infusion and blood pressure monitoring and blood sampling 
respectively. Tracheostomy was performed to maintain a clear airway. The 
urinary bladder was catheterised suprapubically for urine collection. Animals 
were infused intravenously with 0.9% saline containing 3H Inulin (0.5J,JCiml"1) at a 
rate of 200J.Jimin·1 for the first hour to induce rapid volume expansion and 
diuresis. After the establishment of diuresis, the infusion rate was reduced to 
1 OOJ.Jimin-1 of saline containing 3H Inulin (1 JJCiml"1) for the next five hours. The 
five hours were divided into four phases, namely; equilibration phase (1 hour), 
control phase (1 hour), experimental phase (1 hour, where either the drug or the 
vehicle was infused) and recovery phase (2 hours). There were four groups of 
rats, two experimental groups (n = 8) namely: animals receiving nabumetone 
( Smg/kg body weight) and animals receiving indomethacin ( 1.5mg/kg body 
weight) and two control groups (n =8) receiving their respective vehicles. Blood 
and urine samples were collected every 30 minutes for analyses of electrolytes, 
microalbumin and GFR estimation. 
Urine analyses. For urinary sodium and potassium excretion, flame photometer 
(Corning 404, UK) was used. Urinary calcium and magnesium were datermined 
using Hitachi -912 Random Access Chemistry Analyzer from Department of 
Chemical Pathology USM. Urine osmolality was measured using cryoscopic 
osmometer (Osmomat 030, Gonotec, Germany). Urine~ microalbumin was 
determined using turbidity method by kits from Bayer (SEHA -PAK ® immune 
• 
a 
microalbumin, Bayer, USA) using spectrophotometer (Ames Quick-Lab, 
Chemistry analyzer, Germany). [3H] inulin in plasma and urine was assessed by 
liquid scintillation counting using phase combining systern Tri-Carb 31 OOTR 
(Packard Bioscience Company, USA) 
GFR estimation. GFR (glomerular filtration rate) was calculated as the 
clearance of inulin, Cin = UinV/Pin, solute output as UxV, where U and P are 
urinary and plasma concentrations of inulin (in) or solute x respectively and V is 
urine flow rate. 
Statistical analysis. Results are expressed as the mean ± SEM. Statistical 
analysis was performed using analysis of variance (2-way anova) for repeated 
measurements. Significant difference was set at p < 0.05. 
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Figure 1.0: Mean body weight in conscious rats. 
16 20 
There is no significant difference between all groups in terms of body 
weight. But all groups shown increases body weight within study days. 
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Figure 2: Mean food intake in conscious rats. 
No significant difference was detected in food intake t~etween all groups in 
all phases. 
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Figure 3: Mean water intake in conscious rats. 
There is no significant difference in water intake between all groups in 
all phases. 
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Figure 4: Mean urine output in conscious rats. 
In experimental phase, there is a significant difference between 
indomethacin group compared to nabumetone group (p < 0.01 ). In 
th indomethacin group there is reduced urine output compared to 
other groups. In nabumetone group there is increased urine output 
compared to indomethacin group. There is no significant difference 
between groups, indomethacin and nabum,3tone compared to 
control group in urine output. 
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Figure 5: Mean urine sodium output in conscious rats. 
There is no significant difference in sodium output between all groups in 
all phases. 
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Figure 6: Mean urine potassium output in conscious rats. 
There is no significant difference in potassium output between all 
groups in all phases. 
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Figure 7: Mean urine calcium output in conscious rats. 
In Nabumetone group there is increased calcium output on day 18 but 
overall there is no significant difference in calcium output between all 
groups in all phases. 
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Figure 8: Mean urine magnesium output in conscious rats. 
In Nabumetone group there is increased calcium output on day 18 but 
overall there is no significant difference in magnesium output between all 
groups in all phases. 
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Figure 9: Mean urine osmolality in conscious rats. 
In experimental phase, on day 18, there is significant difference 
between indomethacin and nabumetone group. 
indomethacin produced higher urine osmolality compared to 
nabumetone group (p <0.05). But overall, there 1s no 
significant difference between all groups ir all phases in urine 
osmolality. 
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Figure 10: Mean Osmolar output in conscious rats. 
There is no significant difference between all groups in all phases in 
osmolar output. 
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Figure 11: Microalbumin output in conscious rats. 
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There is no significant difference between all groups in all phases 
in microalbumin output. 
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Figure 12: Means urine flow rate in anaesthetiz•~d rats. 
Within nabumetone group, there is decrease in urine flow rate 
especially after 1 hour nabumetone was infuse, however it's no 
significant. However, in overall there is no significant difference 
between all groups in all phases in urine flow rate. 
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Figure 13: Mean glomerular filtration rate in anaesthetized rats. 
There is significant increase glomerular filtration rate within 
nabumetone group between 90 and 150 minutes (i, p<O.OS) after 1 
hour nabumetone was infused. However no significant differences 
were observed between all groups in all phases in glomerular filtration 
rate. 
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Figure 14: Mean sodium output in anaesthetized rats. 
There is significant decrease sodium output in nabumetone group 
compared to indomethacin group in recovery phase 1 (§, p < 0.05). 
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Figure 15: Mean potassium output in anaesthetized rats. 
There is no significant difference in potassium outpu1 between all groups 
in all phases. However. potassium decreases significantly within all 
groups with time. 
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Figure 16: Mean calcium output in anaesthetized rats. 
There is no significant difference between all groups in all phases in 
calcium output. But, within all groups, there is significant decrease 
calcium output with time. 
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Figure 17: Mean magnesium output in anaesthetized rats. 
There is no significant difference between all groups in all phases in 
magnesium output. But, within all groups, there is significant 
decrease magnesium output with time. 
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Figure 18: Mean urine osmolality in anaesthetized rats. 
There is no significant difference between all groups in all phases in 
urine osmolality. 
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Figure 19: Mean osmolar output in anaestheti2~ed rats. 
There is no significant difference between all groups in all phases in 
osmolar output. 
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Figure 20: Mean microalbumin output in anaesthetized rats. 
There is no significant difference between all groups in all phases in 
microalbumin output. 
210 240 
) . 
q 
DISCUSSION 
In experiments using conscious rats, urine output in indon1ethacin group was 
significantly lower compared to nabumetone group towards the end of 
experimental phase (p<0.01 ). Differences appeared starting on day 15 until day 
21. In the nabumetone group urine output was elevated during the same period 
compared to that in the indomethacin group. However, there were no significant 
differences in both indomethacin and nabumetone groups compared to control 
group in urine output during the experimental phase. The effect on urine output 
was reversible and the output was back to normal during recovery phase. There 
were no significant differences in the other parameters measured between the 
three groups in all phases. 
In the previous experiments conducted in our laboratory using naproxen ( a non 
selective COX inhibitor) urine output was higher compared to control group 
during experimental phase (17). Thus, given orally in conscious condition some 
NSAIDs decreased urine output while others increased the urine output. In the 
present experiments with conscious rats, given orally at doses equivalent to 
therapeutic doses employed in humans, only urine output was affected by 
indomethacin ( non selective COX inhibitor) and nabumetone (selective COX-2 
inhibitor). Further study was needed to elucidate the precise mechanism of the 
change in urine output. 
In anaesthetized rats intravenous administration of indomethacin (1.5mg.kg-1 
body weight) and nabumetone (Smg.kg-1 body weight), over 1 hour period with 
urine flow rate 1 001JI.minif1 , there was a decrease in glomerular filtration rate 
(GFR) (P<O.OS), sodium excretion (p<O.OS) in the nabumetone group compared 
to that in the indomethacin group. Urine flow rate and calcium excretion also 
decreased in nabumetone group but not significantly compared to other groups. 
The effects were seen to occur only after 1 hour of infusion but were back to 
normal during recovery phase. 
In the present experiments at a dose equivalent to therapeutic doses employed 
in humans. Indomethacin has not produced any changes in renal function in 
anaesthetized rats experiment. Other study where in higher doses were used 
(1Om g. kg· 1 ) there was decreased G. F. R., decreased urine flow & calcium 
excretion(18). In the present experiments nabumetone produced a decrease in 
GFR and sodium excretion. In a clinical study on patients who were on ACE 
inhibitor and diuretic for osteo arthritis and hypertension, wherein different 
NSAIDS were administered orally but separated by control periods , there was 
no change in renal blood flow or G. F. R but an increased sodium excretion with 
nabumetone (1 OOOmg bid for one month) (19). The difference in the results 
might be due to farmakokinetic factors or due to a different chemical group. 
' 
Nabumetone was nonacidic NSAID compound and has longer half life of 26 
hours compared to indomethacin which is an acetic acid NSAID and has a 
shorter half life of 4 hours (20). 
Between conscious and anaesthetized rats experiments there was no difference 
in the observed effects with indomethacin. However, with nabumetone there was 
a higher urine output in conscious rats and a slight but reversible decrease in 
GFR and sodium excretion in anaesthetized rats. The mechanism was unclear 
but it might be due to dose, farmacokinetic factors and also chemical group. In 
conclusion, this study has not shown much differences in effect on renal function 
between indomethacin and nabumetone in conscious and anaesthetized rats at 
doses equivalent to therapeutic doses employed in humans. 
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